The cholesterol-lowering drug Crestor (rosuvastatin) has been associated with a 27% increased risk of type-2 diabetes in clinical trials. Since then, other studies have confirmed the link between Crestor and diabetes. Our lawyers are concerned that patients are not being properly warned about the danger.
Class Action Lawsuit Information
Class action lawsuits are useful in certain circumstances — for example, when a lot of people buy a truck that was advertised with an inflated MPG. However, for defective drug litigation, they can have disadvantages for individuals who were seriously injured.
Crestor and Type-2 Diabetes
Crestor (rosuvastatin) was associated with an 18% higher risk of diabetes compared to Pravachol (pravastatin), according to a study published in May 2013 by the British Medical Journal. Those conclusions were based on data from 1.5 million people in Canada, including 500,000 who were taking a statin.
The year before that study was published, the FDA also published a Safety Warning after numerous studies linked statins to diabetes. One of these studies, the JUPITER clinical trial, specifically linked Crestor to a 27% increased risk of diabetes